2012 EDUCATIONAL BOOK - American Society of Clinical Oncology

treatment discontinuation: quality of life among postmenopausal women with
primary breast cancer randomized to exemestane or anastrozole. Cancer Res.
2011;71(suppl):S6.
18. Frost J, Okun S, Vaughan T, et al. Patient-reported outcomes as a
source of evidence in off-label prescribing: analysis of data from Patients
LikeMe. J Med Internet Res. 2011;13:e6.
19. McCallister E, Usdin S. A professional trial. BioCentury. 2011;19:A1-
A4.
20. Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary analysis of
3D-CRT vs. IMRT on the high dose arm of the RTOG 0126 prostate cancer
trial: toxicity report. Int J Radiat Oncol Biol Phys. 2011;81(suppl):S1-S2.
144
BRUNER, MOVSAS, AND BASCH
21. Watkins-Bruner D, Hunt D, Michalski J, et al. Preliminary analysis
of 3DCRT vs IMRT on the high dose arm of the RTOG 0126 prostate cancer
trial: patient reported outcomes. Int J Radiat Oncol Biol Phys. 2011;
81(suppl):S44.
22. National Cancer Institute. Patient-Reported Outcomes (PRO) version
of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
2010. http://outcomes.cancer.gov/tools/pro-ctcae.html. Accessed March 20,
2012.
23. Bruner DW. Outcomes research in cancer symptom management trials:
the Radiation Therapy Oncology Group (RTOG) conceptual model. J Natl
Cancer Inst Monogr. 2007;37:12-15.